Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Harvard Medical School (HMS and HSDM)
With
National Institute of Mental Health (NIMH)
Dartmouth-Hitchcock Medical Center
Commonwealth Research Center, Massachusetts
Novartis
This is a longitudinal double-blind 12-week study of the clinical and biochemical response to clozapine or chlorpromazine in a group of treatment-refractory schizophrenic patients.
The study has 4 phases: (1) A recruitment period; (2) a period of discontinuation of psychotropic medication; (3) a drug-washout period; and (4) a 12-week double-blind trial of clozapine or chlorpromazine.
Age
19–60
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
19-60 years of age
Diagnosis of schizophrenia
BPRS score \> 50
Clinical Global Impressions rating \> 4
One of the following: BPRS items rated greater than or equal to 4, conceptual disorganization, suspiciousness, hallucinations, unusual thought content.
At least 2 six-week trials of different neuroleptics given at a dosage equivalent to at least 600 mg per day of chlorpromazine OR at least 1 eight-week trial of a neuroleptic given at a dosage equivalent to at least 800 mg per day of chlorpromazine.
The patient (or the patient's authorized legal representative) must understand the nature of the study and sign the informed consent.
You may not be if
History of substance dependence within the past 2 months
Major medical problems precluding the use of clozapine
Pregnancy or lactation
A serious suicide/homicide risk
Clareo Health | Clozapine Versus Chlorpromazine for Treatment-Unresponsive Schizophrenia
